Tuesday, December 5, 2023
Clinical Advances in
Read Overview
Supported by an independent educational grant from Madrigal Pharmaceuticals
Resources for Patients
Expired Activities
Steering Committee Member Chair
President, Inova Medicine Services
Professor and Chairman
Department of Medicine, Inova Fairfax Medical Campus
Falls Church, Virginia, United States
Professor of Medicine
Mayo Clinic
Rochester, Minnesota, United States
Professor of Experimental Hepatology
and Honorary Consultant Hepatologist
Translational and Clinical Research
Institute Faculty of Medical Sciences
Newcastle University
Newcastle Upon Tyne, United Kingdom
Associate Professor
Harvard Medical School
Director, MGH Fatty Liver Clinic
MGH Gastrointestinal Unit
Massachusetts General Hospital
Boston, Massachusetts, United States
Professor of Medicine
University of California at San Diego
Director of Hepatology
Director, NAFLD Research Center
San Diego, California, United States
Professor
Department of Internal Medicine
Division of Gastroenterology
Hepatology and Nutrition
Virginia Commonwealth University School of Medicine
Richmond, Virginia, United States
Steering Committee Member Chair
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; Gilead Sciences, Inc.; Intercept; Madrigal Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals; Novo Nordisk; Quest; Siemens Healthcare Diagnostics Inc.; Terns Pharmaceuticals
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; Hanmi Pharm Co., Ltd.; Inventiva; NGM Biopharmaceuticals; Novo Nordisk; Madrigal Pharmaceuticals, Inc.; SonicIncytes; Theratherapeutics
Research funding from: Allergan, Inc.; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Durect; Enanta Pharmaceuticals, Inc.; Enyo; Galactin; Galmed Pharmaceuticals Ltd; Genentech, Inc.; Genfit SA; Gilead Sciences, Inc.; Hanmi Pharm Co., Ltd.; Intercept; Inventiva; Madrigal Pharmaceuticals, Inc.; NGM Biopharmaceuticals; Novo Nordisk; Poxel; TARGET Pharmaceuticals; Viking Therapeutics
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: 89Bio; Abbvie/Allergan, Inc.; Akero; Altimentiv; Altimmune; AstraZeneca; Axcella; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; CymaBay; Eli Lilly; Galmed; Genentech, Inc.; Gilead Sciences, Inc.; HistoIndex; Indalo; Intercept Pharma Europe Ltd.; Inventiva; IQVIA; Janssen Pharmaceuticals; Johnson & Johnson; Madrigal Pharmaceuticals, Inc.; MedImmune Inc.; Medpace; Merck & Co., Inc.; Metacrine; NGM Biopharmaceuticals; North Sea Therapeutics; Novartis Pharmaceuticals; Novo Nordisk A/S; PathAI; Pfizer Inc.; Poxel; ProSciento; Roche; SERVIER; Shionogi & Co., Ltd.; Terns Pharmaceuticals
Speaker or member of speakers bureau for: Abbott Laboratories; Allergan/Tobira Therapeutics; Bristol Myers Squibb Company; Clinical Care Options; Falk; Fishawack; Genfit; Gilead Sciences, Inc.; Integritas Communications; Kenes
Research funding from: Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. In addition: Allergan/Tobira Therapeutics; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Glympse Bio; Intercept; Novartis AG; Pfizer Inc.
Royalties from: Elsevier Ltd.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AstraZeneca
Research funding from: Bristol Myers Squibb Company
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: 89Bio; Aardvark Therapeutics; Altimmune; Anylam/Regeneron Pharmaceuticals, Inc.; Amgen Inc.; Arrowhead Pharmaceuticals; AstraZeneca; Bristol Myer Squibb Company; CohBar; Eli Lilly; Galmed; Gilead Sciences, Inc.; Glympse bio; Hightide; Inipharma; Intercept; Inventiva; Ionis; Janssen Inc.; Madrigal Pharmaceuticals, Inc.; Metacrine, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals; Novo Nordisk; Merck & Co., Inc.; Pfizer Inc.; Sagimet; Terns Pharmaceuticals; Theratechnologies Inc.; Viking Therapeutics
Research funding from: Arrowhead Pharmaceuticals; AstraZeneca; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eli Lilly; Galectin Therapeutics; Galmed Pharmaceuticals; Gilead Sciences, Inc.; Hanmi Pharm Co., Ltd.; Intercept; Inventiva; Ionis; Janssen Pharmaceuticals; Madrigal Pharmaceuticals; Merck & Co., Inc.; NGM Biopharmaceuticals; Novo Nordisk; Pfizer Inc.; Sonic Incytes; Terns Pharmaceuticals
Stock options from: LipoNexus Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: 89 Bio; Albireo; Alnylm; Amgen Inc.; AstraZeneca; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eli Lilly; Covance; Gemetech; GenFit; Gilead Sciences, Inc.; Hemoshear; Histoindex; Intercept; Inventiva; Janssen Pharmaceuticals; Madrigal Pharmaceuticals, Inc.; Mallinckrodt Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals; NGM Biopharmaceuticals; Novo Nordisk; Pfizer Inc.; Path AI; Poxel; Prosciento; Regeneron Pharmaceuticals, Inc.; Roche; Salix Pharmaceuticals, Inc.; Siemens Healthcare Diagnostics Inc.; Terns Pharmaceuticals
Research funding from: Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Echosense-Sandhill (ongoing collab with no direct funds to Dr. Sanyal); Eli Lilly; Fractyl; Gilead Sciences, Inc.; Inventiva; Madrigal Pharmaceuticals, Inc.; Mallinckrodt Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals; Novo Nordisk; Seimens (ongoing collab with no direct funds to Dr. Sanyal)
Stock options from: Durect; Exhalenz; Genfit; Indalo; Northsea; Rivus; Sequana; Tiziana